

# **ReNeuron**

*pioneering stem cell therapeutics*

## **2008/09 Annual Report and Accounts**

**Guildford, UK, 31 July 2009:** ReNeuron Group plc (LSE: RENE.L) gives notice that its Annual Report and Accounts for the year ended 31 March 2009 have been sent to shareholders, and are also now available on the Company's website at [www.reneuron.com](http://www.reneuron.com).

Copies have also been submitted to the UK Listing Authority for publication through the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

### ***Enquiries:***

Michael Hunt, Chief Executive Officer - ReNeuron	+44 (0) 1483 302560
Jonathan Birt, Susan Quigley – Financial Dynamics	+44 (0) 20 7831 3113
Stewart Wallace, Adam Cowen – Collins Stewart	+44 (0) 20 7523 8350

### **About ReNeuron**

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron recently received regulatory approval to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its *ReNcell*<sup>®</sup> products for use in academic and commercial research. The Company's *ReNcell*<sup>®</sup>CX and *ReNcell*<sup>®</sup>VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at [www.reneuron.com](http://www.reneuron.com).

*This announcement contains forward-looking statements with respect to the financial condition, results of operations and business*

*achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.*